Ventaleon Appoints Dr. Ulrich Dauer as Chief Executive Officer

  • Well-known industry executive joins to grow company as it enters late-stage clinical development

Gemuenden, Germany, 24 May, 2017 – Ventaleon GmbH today announced that long-time biotech executive and entrepreneur, Dr. Ulrich Dauer, has joined the company as Chief Executive Officer. He succeeds Dr. Gerhard Scheuch who will continue to serve as a member of the Supervisory Board of Ventaleon.

“We would like to warmly thank Dr. Scheuch for his strong commitment and leadership in advancing Ventaleon’s business and are delighted that he will remain on the Board. His insight and expertise will continue to be highly valuable as the company advances,“ said Dr. Jean Luechinger, Chairman of Ventaleon’s Supervisory Board. He continued: “We are very pleased to have Dr. Dauer lead Ventaleon. He is joining the company at a critical time as it advances into late-stage clinical development. With many years of effectively leading biotechs, forming strong collaborations with the pharmaceutical industry and successfully completing major financial transactions, Dr. Dauer has the ideal skill set to take Ventaleon to the next stage of growth.“

Dr. Dauer has many years of senior executive management experience. He most recently served as Chief Executive Officer of OMEICOS Therapeutics GmbH. Previously he was Chief Strategy Officer at Activaero GmbH, where he led the transaction team responsible for the EUR 130 million sale of Activaero to Vectura plc. In 1997, he founded 4SC AG, serving as CEO for fourteen years, which included taking the company public, building a clinical pipeline and successfully concluding numerous partnerships. Dr. Dauer received his PhD in natural sciences from Julius-Maximilians Universitaet Wuerzburg.

“I am excited to join Ventaleon,“ said Dr. Ulrich Dauer, Chief Executive Officer. “I know Ventaleon’s technology very well from my time at Activaero and believe that the novel inhaled antiviral agents that Ventaleon is developing have the potential to help patients suffering from serious infections such as influenza to get better, faster. I very much look forward to growing the company and advancing it into the next stages of development.“

For further information, please contact:

Contact
Ventaleon  GmbH
Dr. Ulrich Dauer, CEO
Tel: +49-6453-58530-40
 E-Mail: Diese E-Mail-Adresse ist vor Spambots gesch├╝tzt! Zur Anzeige muss JavaScript eingeschaltet sein!

Media Inquiries 
MC Services AG
Katja Arnold, Dr. Brigitte Keller
Tel: +49 89 21022 0
E-Mail: Diese E-Mail-Adresse ist vor Spambots gesch├╝tzt! Zur Anzeige muss JavaScript eingeschaltet sein!

About Ventaleon GmbH: www.ventaleon.com

Ventaleon GmbH is a biotechnology company focused on the development of inhaled treatments against viral infections. The Company’s lead therapy candidate is an inhaled form of LASAG (D,L-lysine acetylsalicylate • glycine), which it is developing to treat severe influenza. A proof-of-concept study in influenza patients with moderate to severe symptoms demonstrated more rapid symptom decline when administered inhaled LASAG compared to standard of care. The Company is currently preparing to enter a pivotal clinical trial with inhaled LASAG. Ventaleon was founded as a spin-off from Activaero and is supported by a group of leading international investors, including Coöperatief LSP U.A,. BioMedInvest II LP, Abalis Finance AG, Vesalius Biocapital I S.A., Venture Incubator AG, CatheyWorldInvestment Ltd. and BayBg.